NUPLAZID^® (pimavanserin) was granted Breakthrough Therapy designation for the treatment of hallucinations and delusions associated with Parkinson's disease-psychosis by the FDA in 2014.

Before NUPLAZID there was no FDA-approved treatment for Parkinson's disease-related hallucinations and delusions.

NUPLAZID was granted Breakthrough Therapy designation for the treatment of hallucinations and delusions associated with Parkinson's disease-psychosis by the FDA in 2014. Breakthrough Therapy designation is an expedited program that applies to drugs that address an important unmet medical need and may provide a substantial improvement over existing (or nonexisting) treatments based on early clinical data.